Trial Profile
A randomized, multicenter, phase II evaluation of ONTAK (Denileukin diftitox) in patients with previously treated, indolent, B-cell, non-Hodgkin's lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 12 May 2009 Lead trial investigator (Lombardy E) identified as reported by ClinicalTrials.gov.
- 12 May 2009 Lead trial investigator (Lombardy E) identified as reported by ClinicalTrials.gov.
- 12 May 2009 Actual end date (1 Sep 2006) added as reported by ClinicalTrials.gov.